Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition in participants with LN (LN Cohort) or IgAN (IgAN Cohort).
Epistemonikos ID: 2aeef2c16504ff44dda09d21b654bdf510c8ffa9
First added on: May 07, 2024